علاج التهاب القصيبات الضام لدى متلقي زراعة الرئة مع تراجع FEV1

References

1. For lung transplant recipients who develop a decline in FEV1 consistent with the onset of BOS, we suggest a trial of azithromycin (conditional recommendation, very low quality evidence).
2. Azithromycin is generally administered orally at 250 mg per day for 5 days and then 250 mg three times per week.
3. We define a trial of azithromycin as treating continuously with azithromycin for a minimum of 3 months.
4. The studies found that 30–83% of patients had improved lung function (defined as an increase in FEV1 of ≥10%) after receiving azithromycin, even though the mean FEV1 did not increase in some studies because nonresponders continued to have lung function decline.

DOI: 10.1183/09031936.00107514